IL163066A - Ligands for the zcytor17 receptor - Google Patents

Ligands for the zcytor17 receptor

Info

Publication number
IL163066A
IL163066A IL163066A IL16306604A IL163066A IL 163066 A IL163066 A IL 163066A IL 163066 A IL163066 A IL 163066A IL 16306604 A IL16306604 A IL 16306604A IL 163066 A IL163066 A IL 163066A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid residues
ligands
zcytor17 receptor
Prior art date
Application number
IL163066A
Other languages
English (en)
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of IL163066A publication Critical patent/IL163066A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
IL163066A 2002-01-18 2004-07-15 Ligands for the zcytor17 receptor IL163066A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35032502P 2002-01-18 2002-01-18
US37532302P 2002-04-25 2002-04-25
US43531502P 2002-12-19 2002-12-19
PCT/US2003/001984 WO2003060090A2 (en) 2002-01-18 2003-01-21 Novel cytokine zcytor17 ligand

Publications (1)

Publication Number Publication Date
IL163066A true IL163066A (en) 2011-08-31

Family

ID=27407940

Family Applications (3)

Application Number Title Priority Date Filing Date
IL163066A IL163066A (en) 2002-01-18 2004-07-15 Ligands for the zcytor17 receptor
IL210455A IL210455A (en) 2002-01-18 2011-01-04 A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
IL210454A IL210454A (en) 2002-01-18 2011-01-04 Antibody against a new ligand of cytokine 17zcytor

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL210455A IL210455A (en) 2002-01-18 2011-01-04 A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
IL210454A IL210454A (en) 2002-01-18 2011-01-04 Antibody against a new ligand of cytokine 17zcytor

Country Status (21)

Country Link
US (12) US7064186B2 (enExample)
EP (3) EP1476541B1 (enExample)
JP (1) JP4795641B2 (enExample)
KR (1) KR101013401B1 (enExample)
CN (2) CN100575482C (enExample)
AT (3) ATE401390T1 (enExample)
AU (2) AU2003225525B2 (enExample)
BR (1) BR0306979A (enExample)
CA (1) CA2473686C (enExample)
CY (1) CY1112833T1 (enExample)
DE (2) DE60322188D1 (enExample)
DK (3) DK2230299T3 (enExample)
ES (3) ES2351678T3 (enExample)
IL (3) IL163066A (enExample)
NO (1) NO332266B1 (enExample)
PL (1) PL211833B1 (enExample)
PT (1) PT2230299E (enExample)
RU (2) RU2490276C2 (enExample)
SI (1) SI2230299T1 (enExample)
WO (1) WO2003060090A2 (enExample)
ZA (1) ZA200405695B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
JP4511349B2 (ja) * 2002-01-18 2010-07-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー
EP1476541B1 (en) 2002-01-18 2008-07-16 ZymoGenetics, Inc. Cytokine (zcytor17 ligand)
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
WO2005040380A1 (ja) * 2003-10-29 2005-05-06 Bml, Inc. げっ歯類動物の免疫応答調節蛋白質
JP2007068402A (ja) * 2003-12-26 2007-03-22 Bml Inc 免疫応答調節蛋白質
JP5179189B2 (ja) 2004-11-03 2013-04-10 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｔ細胞タンパク質及びそれをコードするヌクレオチド
ES2579758T3 (es) * 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
EP1856150A2 (en) * 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
WO2006088855A1 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
EP1869222A4 (en) * 2005-04-15 2010-01-20 Oncomethylome Sciences S A METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
JP5065253B2 (ja) * 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
MX2008008831A (es) * 2006-01-10 2009-03-04 Zymogenetics Inc Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31.
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
PE20080333A1 (es) 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias
DK2594586T3 (en) * 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
AU2008204823A1 (en) * 2007-01-10 2008-07-17 Zymogenetics, Inc Methods of using IL-31 to treat airway hyper-responsiveness and asthma
DK2202245T3 (en) * 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
WO2009052487A2 (en) * 2007-10-18 2009-04-23 University Of South Florida Method of detecting oncogenesis of hematopoietic cells
MY162546A (en) 2007-12-05 2017-06-15 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
MX337081B (es) * 2007-12-05 2016-02-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-nr10 y su uso.
AU2008333131B2 (en) 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
WO2009147537A2 (en) 2008-05-27 2009-12-10 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
EP2401395A1 (en) 2009-02-26 2012-01-04 Dako Denmark A/S Compositions and methods for rna hybridization applications
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013025248A1 (en) * 2011-08-12 2013-02-21 Mello Biotechnology, Inc. Inducable expression from the eukaryotic pol -2 promoter in prokaryotes
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
US10196662B2 (en) * 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
KR101882366B1 (ko) 2013-05-30 2018-07-30 키닉사 파마슈티컬스, 리미티드 온코스타틴 m 수용체 항원 결합 단백질
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
US20170072019A1 (en) 2014-05-12 2017-03-16 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising il-31 and uses thereof
ES3036076T3 (en) 2015-04-14 2025-09-12 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
CN104826100A (zh) * 2015-04-16 2015-08-12 浙江海隆生物科技有限公司 一种猪瘟病毒重组亚单位疫苗的制备方法与应用
DE102015215840B4 (de) * 2015-08-19 2017-03-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multiaperturabbildungsvorrichtung, Abbildungssystem und Verfahren zum Bereitstellen einer Multiaperturabbildungsvorrichtung
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
CN111337666B (zh) * 2020-02-12 2021-04-02 山东大学 I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用
TWI765431B (zh) * 2020-11-25 2022-05-21 長庚大學 核酸放大系統及其方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054646A (en) * 1973-07-30 1977-10-18 General Electric Method and apparatus for detection of antibodies and antigens
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0184576B1 (en) 1984-12-06 1990-06-27 Fina Research S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
ATE140963T1 (de) 1988-01-22 1996-08-15 Zymogenetics Inc Verfahren zur herstellung von sekretierten rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6217857B1 (en) * 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP0749319A1 (en) 1992-09-14 1996-12-27 Pfizer Inc. Immortalized cells and uses therefor
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5492841A (en) * 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
RU2102988C1 (ru) * 1995-02-10 1998-01-27 Зинченко Елена Вениаминовна Препарат с иммуномодулирующими свойствами
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
WO1997017451A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US6265184B1 (en) * 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
GB9819420D0 (en) 1998-09-07 1998-10-28 Glaxo Group Ltd Novel receptor
JP2002543786A (ja) * 1999-05-11 2002-12-24 ザイモジェネティクス，インコーポレイティド サイトカイン受容体マウスｚｃｙｔｏｒ１０
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004501628A (ja) * 2000-06-26 2004-01-22 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１７
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
CA2416456A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2005507632A (ja) 2000-10-06 2005-03-24 イミュネックス・コーポレーション ヘマトポエチン受容体、ｈｐｒ１およびｈｐｒ２
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
JP4511349B2 (ja) 2002-01-18 2010-07-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１７マルチマー
EP1476541B1 (en) 2002-01-18 2008-07-16 ZymoGenetics, Inc. Cytokine (zcytor17 ligand)
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
JP2008534915A (ja) * 2005-01-19 2008-08-28 アイアールエム・リミテッド・ライアビリティ・カンパニー 複数窪み容器の位置決め装置、システム、コンピュータ・プログラム生成物、及び方法
ES2579758T3 (es) * 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
EP1856150A2 (en) * 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
WO2006088855A1 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
MX2008008831A (es) 2006-01-10 2009-03-04 Zymogenetics Inc Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31.
DK2594586T3 (en) 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
AU2008204823A1 (en) 2007-01-10 2008-07-17 Zymogenetics, Inc Methods of using IL-31 to treat airway hyper-responsiveness and asthma
AU2008333131B2 (en) 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31

Also Published As

Publication number Publication date
US20060141579A1 (en) 2006-06-29
BR0306979A (pt) 2004-11-23
IL210455A (en) 2014-02-27
EP1961811A1 (en) 2008-08-27
AU2008230054A1 (en) 2008-11-13
PL211833B1 (pl) 2012-06-29
DK1476541T3 (da) 2008-11-03
CA2473686A1 (en) 2003-07-24
US20090149635A1 (en) 2009-06-11
EP1961811B1 (en) 2010-08-25
DK1961811T3 (da) 2010-11-08
DE60322188D1 (de) 2008-08-28
ZA200405695B (en) 2005-03-30
AU2008230054B2 (en) 2012-01-19
IL210454A0 (en) 2011-03-31
KR101013401B1 (ko) 2011-02-14
PL371586A1 (en) 2005-06-27
US20130156695A1 (en) 2013-06-20
IL210455A0 (en) 2011-03-31
US7740834B2 (en) 2010-06-22
US20150010946A1 (en) 2015-01-08
RU2490276C2 (ru) 2013-08-20
EP1476541B1 (en) 2008-07-16
US20110196128A1 (en) 2011-08-11
EP2230299A1 (en) 2010-09-22
WO2003060090A2 (en) 2003-07-24
EP1476541A4 (en) 2006-01-11
US20070077627A1 (en) 2007-04-05
US8124378B2 (en) 2012-02-28
CN1643138A (zh) 2005-07-20
DE60333963D1 (de) 2010-10-07
ATE478944T1 (de) 2010-09-15
US20030224487A1 (en) 2003-12-04
RU2004125165A (ru) 2005-04-20
KR20040082394A (ko) 2004-09-24
CA2473686C (en) 2011-09-20
DK2230299T3 (da) 2012-03-26
SI2230299T1 (sl) 2012-07-31
EP2230299B1 (en) 2011-12-07
AU2003225525A1 (en) 2003-07-30
US20180155418A1 (en) 2018-06-07
CN100575482C (zh) 2009-12-30
IL210454A (en) 2014-02-27
AU2003225525B2 (en) 2008-07-24
CN101843895A (zh) 2010-09-29
US20190338020A1 (en) 2019-11-07
ES2310660T3 (es) 2009-01-16
CY1112833T1 (el) 2016-02-10
ES2377188T3 (es) 2012-03-23
US20090192292A1 (en) 2009-07-30
WO2003060090A3 (en) 2004-04-01
US7507795B2 (en) 2009-03-24
ES2351678T3 (es) 2011-02-09
US9605062B2 (en) 2017-03-28
JP2005526494A (ja) 2005-09-08
US7459293B2 (en) 2008-12-02
US8013124B2 (en) 2011-09-06
US8778344B2 (en) 2014-07-15
US7531636B2 (en) 2009-05-12
RU2360923C2 (ru) 2009-07-10
US7425325B2 (en) 2008-09-16
NO20043419L (no) 2004-10-18
JP4795641B2 (ja) 2011-10-19
US20070111266A1 (en) 2007-05-17
EP1476541A2 (en) 2004-11-17
RU2008118227A (ru) 2009-11-20
ATE536406T1 (de) 2011-12-15
PT2230299E (pt) 2012-03-02
ATE401390T1 (de) 2008-08-15
US7064186B2 (en) 2006-06-20
US20070249020A1 (en) 2007-10-25
NO332266B1 (no) 2012-08-13

Similar Documents

Publication Publication Date Title
IL163066A (en) Ligands for the zcytor17 receptor
IL226637A0 (en) An isolated heterodimeric cytokine receptor
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
ATE441666T1 (de) Antikírper gegen den fibroblastenwachstumsfaktor 23
ATE390441T1 (de) Niedrigallergene proteinvarianten
AU2003296151A1 (en) Process for producing dipeptide
DK1114156T3 (da) Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
GB0309126D0 (en) Clostridium difficile focussed antibodies
WO2002102847A1 (fr) Nouveau ligand et son adn
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
WO2003021262A1 (fr) Procede de criblage
WO2000019207A3 (de) Verfahren zur bestimmung von atrialem natriuretischem peptid (anp)
AU2003202489A1 (en) Screening method
AU2456600A (en) The ltr region of msrv-1 and the proteins it encodes, and probes and methods fordetecting msrv-1 retrovirus
IL142664A0 (en) Prv-1 gene, processes for detecting the prv-1 polypeptide and pharmaceutical compositions containing the same
WO2003027150A1 (fr) Anticorps et son utilisation
WO2002061074A1 (fr) Nouvelle proteine et adn la comprenant
WO2003021263A1 (fr) Utilisation d'une proteine de recepteur couple a une proteine g
WO2003045994A1 (fr) Nouveau ligand et adn de ce ligand
EP1225183A3 (en) Human G-protein coupled receptor
WO2002029053A1 (fr) Nouvelle proteine de recepteur couple a la proteine g et adn correspondant
JP2000037187A5 (enExample)
NZ606260A (en) Novel polypeptides involved in immune response
AU2001277717A1 (en) Novel proteins and dnas thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees